Important shareholder alert: lundin law pc announces securities class action lawsuit against insmed incorporated and reminds investors with losses to contact the firm

Los angeles--(business wire)--lundin law pc announces a class action lawsuit has been filed against insmed incorporated ("insmed" or the "company") (nasdaq: insm) concerning possible violations of federal securities laws between march 18, 2013 and june 8, 2016 (the “class period”). investors who purchased or otherwise acquired shares during the class period should contact the firm in advance of the september 13, 2016 lead plaintiff motion deadline. to participate in this class action lawsuit, click here. you can also call brian lundin, esquire, of lundin law pc, at 888-713-1033, or e-mail him at brian@lundinlawpc.com. no class has been certified in the above action. until a class is certified, you are not considered represented by an attorney. you may also choose to do nothing and be an absent class member. according to the complaint, insmed made false and/or misleading statements and/or failed to disclose that: the data on which insmed’s european marketing authorization application relied for its lead product candidate for the treatment of ntm lung disease, arikayce, was not likely to support approval by the european medicines agency (“ema”); arikayce’s approval by the ema for the treatment of ntm lung disease and subsequent commercialization in europe were thus less likely than the company had led investors to believe; and as a result of the above, insmed’s public statements were materially false and misleading at all relevant times. lundin law pc was created by brian lundin, a securities litigator based in los angeles. this press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.
INSM Ratings Summary
INSM Quant Ranking